HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boots partners with P&G in Italy

This article was originally published in The Rose Sheet

Executive Summary

As part of its European expansion initiative, U.K.-based beauty and pharmacy group Alliance Boots has partnered with Procter & Gamble in Italy. Boots will "leverage P&G's sales force capacity to distribute and promote" its Boots Laboratories skin-care range to pharmacies in the country, firm says. The line - boasting "clinically proven anti-aging benefits" - launched in France and Portugal in the last two years. Boots plans to launch the range in Italy and Spain in the coming months. "Our objective is to expand Boots Laboratories, and we are delighted to be working in partnership with P&G to make these award-winning products accessible to Italian consumers," Ornella Barra, chief executive of Boots' pharmaceutical wholesale division, says in a release

You may also be interested in...



Warning Letter Roundup & Recap – 2 June 2020

No device-related warning letters were released by the US FDA the week of 2 June.

Medtronic Brain Imaging Software Recalled After 11 Injuries

The Minnesota-based medtech giant has had to yank a software used on its SealthStation platforms used to help surgeons navigate a patient’s brain during surgery. However, minor movements by the patient have been found to give false imaging that could endanger the patient’s life.

European CHMP Opinions and MAA Updates

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.

UsernamePublicRestriction

Register

PS026881

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel